Aytu Biopharma (AYTU) Research & Development (2014 - 2025)

Aytu Biopharma (AYTU) has 12 years of Research & Development data on file, last reported at $6.0 million in Q4 2025.

• On a quarterly basis, Research & Development rose 13.77% year-over-year to $6.0 million in Q4 2025; TTM through Mar 2026 was -$3.5 million, a 121.33% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, down 94.0% from the prior year.
• Research & Development for Q4 2025 stood at $6.0 million, up from $5.3 million in the prior quarter.
• Over the last five years, Research & Development for AYTU reached as high as $29.4 million in Q2 2021 and fell as low as -$14.8 million in Q2 2025.
• Historically, Research & Development has averaged $6.2 million across 5 years, with a median of $5.3 million in 2024.
• Across the five-year window, Research & Development soared 4980.33% in 2021 and sank 372.94% in 2025, its largest moves.
• Year by year, Research & Development stood at $9.7 million in 2021, then slumped by 82.3% to $1.7 million in 2022, then tumbled by 69.53% to $521000.0 in 2023, then surged by 911.9% to $5.3 million in 2024, then rose by 13.77% to $6.0 million in 2025.
• Per Business Quant data, the three most recent Research & Development figures were $6.0 million in Q4 2025, $5.3 million in Q3 2025, and -$14.8 million in Q2 2025.